Dose‐response relationship for mivacurium inpatients with phenotypically abnormal plasma cholinesterase activity

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Dose‐response relationship for mivacurium inpatients with phenotypically abnormal plasma cholinesterase activity. / OSTERGAARD, D.; JENSEN, F. S.; SKOVGAARD, L. THEIL; VIBY‐MOGENSEN, J.

I: Acta Anaesthesiologica Scandinavica, Bind 39, Nr. 8, 11.1995, s. 1016-1018.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

OSTERGAARD, D, JENSEN, FS, SKOVGAARD, LTHEIL & VIBY‐MOGENSEN, J 1995, 'Dose‐response relationship for mivacurium inpatients with phenotypically abnormal plasma cholinesterase activity', Acta Anaesthesiologica Scandinavica, bind 39, nr. 8, s. 1016-1018. https://doi.org/10.1111/j.1399-6576.1995.tb04220.x

APA

OSTERGAARD, D., JENSEN, F. S., SKOVGAARD, L. THEIL., & VIBY‐MOGENSEN, J. (1995). Dose‐response relationship for mivacurium inpatients with phenotypically abnormal plasma cholinesterase activity. Acta Anaesthesiologica Scandinavica, 39(8), 1016-1018. https://doi.org/10.1111/j.1399-6576.1995.tb04220.x

Vancouver

OSTERGAARD D, JENSEN FS, SKOVGAARD LTHEIL, VIBY‐MOGENSEN J. Dose‐response relationship for mivacurium inpatients with phenotypically abnormal plasma cholinesterase activity. Acta Anaesthesiologica Scandinavica. 1995 nov.;39(8):1016-1018. https://doi.org/10.1111/j.1399-6576.1995.tb04220.x

Author

OSTERGAARD, D. ; JENSEN, F. S. ; SKOVGAARD, L. THEIL ; VIBY‐MOGENSEN, J. / Dose‐response relationship for mivacurium inpatients with phenotypically abnormal plasma cholinesterase activity. I: Acta Anaesthesiologica Scandinavica. 1995 ; Bind 39, Nr. 8. s. 1016-1018.

Bibtex

@article{859d59ef9cd848bb9e4a8062789bffb9,
title = "Dose‐response relationship for mivacurium inpatients with phenotypically abnormal plasma cholinesterase activity",
abstract = "During thiopentone‐fentanyl‐nitrous oxide anaesthesia and using a cumulative design, we studied the dose‐response relationship of mivacurium in 8 patients: 7 patients phenotypically homozygous for the atypical plasma cholinesterase gene and 1 patient homozygous for the silent gene. The estimated mean ED50 and ED95 were 15 and 20 μg. kg. bw‐1 in patients homozygous for the atypical gene, and 13 and 16 μg. kg. bw‐1 in the patient homozygous for the silent gene, respectively. The results indicate that mivacurium is 4‐5 times more potent in patients homozygous for the atypical or the silent gene than in patients with normal plasma cholinesterase activity and phenotype.",
keywords = "Anesthetics, butyrylcholinesterase, enzymes: cholinesterase, intravenous: fentanyl, mivacurium, neuromuscular relaxants, pharmacology: dose‐response cumes, pseudocholinesterase",
author = "D. OSTERGAARD and JENSEN, {F. S.} and SKOVGAARD, {L. THEIL} and J. VIBY‐MOGENSEN",
year = "1995",
month = nov,
doi = "10.1111/j.1399-6576.1995.tb04220.x",
language = "English",
volume = "39",
pages = "1016--1018",
journal = "Acta Anaesthesiologica Scandinavica",
issn = "0001-5172",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Dose‐response relationship for mivacurium inpatients with phenotypically abnormal plasma cholinesterase activity

AU - OSTERGAARD, D.

AU - JENSEN, F. S.

AU - SKOVGAARD, L. THEIL

AU - VIBY‐MOGENSEN, J.

PY - 1995/11

Y1 - 1995/11

N2 - During thiopentone‐fentanyl‐nitrous oxide anaesthesia and using a cumulative design, we studied the dose‐response relationship of mivacurium in 8 patients: 7 patients phenotypically homozygous for the atypical plasma cholinesterase gene and 1 patient homozygous for the silent gene. The estimated mean ED50 and ED95 were 15 and 20 μg. kg. bw‐1 in patients homozygous for the atypical gene, and 13 and 16 μg. kg. bw‐1 in the patient homozygous for the silent gene, respectively. The results indicate that mivacurium is 4‐5 times more potent in patients homozygous for the atypical or the silent gene than in patients with normal plasma cholinesterase activity and phenotype.

AB - During thiopentone‐fentanyl‐nitrous oxide anaesthesia and using a cumulative design, we studied the dose‐response relationship of mivacurium in 8 patients: 7 patients phenotypically homozygous for the atypical plasma cholinesterase gene and 1 patient homozygous for the silent gene. The estimated mean ED50 and ED95 were 15 and 20 μg. kg. bw‐1 in patients homozygous for the atypical gene, and 13 and 16 μg. kg. bw‐1 in the patient homozygous for the silent gene, respectively. The results indicate that mivacurium is 4‐5 times more potent in patients homozygous for the atypical or the silent gene than in patients with normal plasma cholinesterase activity and phenotype.

KW - Anesthetics

KW - butyrylcholinesterase

KW - enzymes: cholinesterase

KW - intravenous: fentanyl

KW - mivacurium

KW - neuromuscular relaxants

KW - pharmacology: dose‐response cumes

KW - pseudocholinesterase

U2 - 10.1111/j.1399-6576.1995.tb04220.x

DO - 10.1111/j.1399-6576.1995.tb04220.x

M3 - Journal article

C2 - 8607300

AN - SCOPUS:0028827688

VL - 39

SP - 1016

EP - 1018

JO - Acta Anaesthesiologica Scandinavica

JF - Acta Anaesthesiologica Scandinavica

SN - 0001-5172

IS - 8

ER -

ID: 259165343